$ATRA
Atara Biotherapeutics, Inc.

2020 Q1 Form 10-Q Financial Statement

#000156459020021960 Filed on May 06, 2020

View on sec.gov

Income Statement

Concept 2020 Q1 2019 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $17.04M $19.22M
YoY Change -11.34% 37.38%
% of Gross Profit
Research & Development $57.66M $48.67M
YoY Change 18.47% 71.01%
% of Gross Profit
Depreciation & Amortization $1.950M $1.650M
YoY Change 18.18% 400.0%
% of Gross Profit
Operating Expenses $74.70M $67.89M
YoY Change 10.03% 138.55%
Operating Profit
YoY Change
Interest Expense $1.190M $1.630M
YoY Change -26.99% 61.39%
% of Operating Profit
Other Income/Expense, Net $1.188M $1.634M
YoY Change -27.29%
Pretax Income -$73.51M -$66.26M
YoY Change 10.94% 59.89%
Income Tax
% Of Pretax Income
Net Earnings -$73.51M -$66.26M
YoY Change 10.95% 59.88%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$1.201M -$1.437M
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q1 2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $214.6M $237.5M
YoY Change -9.64% -41.69%
Cash & Equivalents $70.20M $57.56M
Short-Term Investments $144.4M $181.4M
Other Short-Term Assets $14.60M $13.30M
YoY Change 9.77% 111.11%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $229.2M $250.8M
YoY Change -8.61% -39.36%
LONG-TERM ASSETS
Property, Plant & Equipment $54.44M $72.20M
YoY Change -24.6% 24.05%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.200M $1.700M
YoY Change 29.41% 30.77%
Total Long-Term Assets $70.30M $73.90M
YoY Change -4.87% 24.2%
TOTAL ASSETS
Total Short-Term Assets $229.2M $250.8M
Total Long-Term Assets $70.30M $73.90M
Total Assets $299.5M $324.7M
YoY Change -7.76% -31.37%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $8.100M $6.200M
YoY Change 30.65% 1.64%
Accrued Expenses $17.50M $14.30M
YoY Change 22.38% 34.91%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $400.0K
YoY Change
Total Short-Term Liabilities $31.50M $25.20M
YoY Change 25.0% 20.0%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $200.0K
YoY Change -100.0%
Other Long-Term Liabilities $15.20M $1.180M
YoY Change 1188.14% -90.85%
Total Long-Term Liabilities $15.20M $1.180M
YoY Change 1188.14% -90.85%
TOTAL LIABILITIES
Total Short-Term Liabilities $31.50M $25.20M
Total Long-Term Liabilities $15.20M $1.180M
Total Liabilities $46.70M $40.79M
YoY Change 14.48% 20.33%
SHAREHOLDERS EQUITY
Retained Earnings -$891.5M -$593.2M
YoY Change 50.28%
Common Stock $877.1M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $252.8M $283.9M
YoY Change
Total Liabilities & Shareholders Equity $299.5M $324.7M
YoY Change -7.77% -31.36%

Cashflow Statement

Concept 2020 Q1 2019 Q1
OPERATING ACTIVITIES
Net Income -$73.51M -$66.26M
YoY Change 10.95% 59.88%
Depreciation, Depletion And Amortization $1.950M $1.650M
YoY Change 18.18% 400.0%
Cash From Operating Activities -$67.04M -$70.20M
YoY Change -4.5% 101.6%
INVESTING ACTIVITIES
Capital Expenditures $1.333M $796.0K
YoY Change 67.46% -95.98%
Acquisitions
YoY Change
Other Investing Activities $40.31M $68.39M
YoY Change -41.06% -129.72%
Cash From Investing Activities $38.97M $67.60M
YoY Change -42.34% -127.05%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $24.28M $0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 23.96M -1.926M
YoY Change -1343.87% -100.65%
NET CHANGE
Cash From Operating Activities -67.04M -70.20M
Cash From Investing Activities 38.97M 67.60M
Cash From Financing Activities 23.96M -1.926M
Net Change In Cash -4.114M -4.530M
YoY Change -9.18% -140.19%
FREE CASH FLOW
Cash From Operating Activities -$67.04M -$70.20M
Capital Expenditures $1.333M $796.0K
Free Cash Flow -$68.38M -$71.00M
YoY Change -3.69% 29.96%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q1 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2012-08-01
CY2020Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17038000
CY2019Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
19223000
CY2020Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1188000
CY2019Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1634000
CY2020Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-16000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-73509000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-73509000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-66257000
CY2019Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
378000
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.44
CY2020Q1 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
1395000
CY2020Q1 atra Issuance Of Common Stock Pursuant To Employee Stock Awards Value
IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue
1330000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
12644000
CY2018Q4 us-gaap Cumulative Effect Of New Accounting Principle In Period Of Adoption
CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
364000
CY2018Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest Adjusted Balance1
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1
339221000
CY2019Q1 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
4575000
CY2019Q1 atra Issuance Of Common Stock Pursuant To Employee Stock Awards Value
IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue
2898000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
12269000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-66257000
CY2019Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
378000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
283934000
CY2020Q1 us-gaap Profit Loss
ProfitLoss
-73509000
CY2019Q1 us-gaap Profit Loss
ProfitLoss
-66257000
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
12644000
CY2019Q1 us-gaap Share Based Compensation
ShareBasedCompensation
12269000
CY2020Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1949000
CY2019Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1648000
CY2020Q1 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-42000
CY2019Q1 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
458000
CY2020Q1 atra Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
364000
CY2019Q1 atra Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
331000
CY2020Q1 us-gaap Accretion Expense
AccretionExpense
19000
CY2019Q1 us-gaap Accretion Expense
AccretionExpense
17000
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1888000
CY2019Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1434000
CY2020Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
209000
CY2019Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-38000
CY2020Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-590000
CY2019Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2672000
CY2020Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-5030000
CY2019Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-3177000
CY2020Q1 atra Increase Decrease In Accrued Research And Development
IncreaseDecreaseInAccruedResearchAndDevelopment
-514000
CY2019Q1 atra Increase Decrease In Accrued Research And Development
IncreaseDecreaseInAccruedResearchAndDevelopment
-13016000
CY2020Q1 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-169000
CY2019Q1 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-2572000
CY2020Q1 atra Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-153000
CY2019Q1 atra Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-261000
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-67044000
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-70200000
CY2020Q1 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
56851000
CY2019Q1 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
7427000
CY2020Q1 us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
97157000
CY2019Q1 us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
75819000
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1333000
CY2019Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
796000
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
38973000
CY2019Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
67596000
CY2020Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
24277000
CY2019Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
2747000
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
23957000
CY2019Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1926000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-4114000
CY2019Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
CY2020Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1330000
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-4530000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
75711000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
62092000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
71597000
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
57562000
CY2020Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1098000
CY2019Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
666000
CY2020Q1 atra Finance Lease Assets Obtained In Exchange For Lease Obligations
FinanceLeaseAssetsObtainedInExchangeForLeaseObligations
281000
CY2019Q1 atra Finance Lease Assets Obtained In Exchange For Lease Obligations
FinanceLeaseAssetsObtainedInExchangeForLeaseObligations
0
CY2020Q1 atra Accrued Costs Of Financing Activities Charged To Stockholders Equity
AccruedCostsOfFinancingActivitiesChargedToStockholdersEquity
112000
CY2019Q1 atra Accrued Costs Of Financing Activities Charged To Stockholders Equity
AccruedCostsOfFinancingActivitiesChargedToStockholdersEquity
0
CY2020Q1 atra Receivable For Options Exercised
ReceivableForOptionsExercised
0
CY2019Q1 atra Receivable For Options Exercised
ReceivableForOptionsExercised
151000
CY2020Q1 us-gaap Interest Paid Net
InterestPaidNet
17000
CY2019Q1 us-gaap Interest Paid Net
InterestPaidNet
0
CY2020Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
CY2019Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
CY2020Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1395000
CY2019Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
4575000
CY2020Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
90000
CY2019Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
98000
CY2020Q1 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-165000
CY2019Q1 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
0
CY2020Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2020Q1 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
38274000
CY2020Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-891500000
CY2020Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, assumptions, and judgments that affect the amounts reported in the financial statements and accompanying notes. Significant estimates relied upon in preparing these financial statements include estimates related to clinical trial and other accruals, stock-based compensation expense and income taxes. Actual results could differ materially from those estimates. </p>
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11905581
CY2019Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8740355
CY2020Q1 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
174851000
CY2020Q1 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
174853000
CY2019Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
214085000
CY2019Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
214199000
CY2020Q1 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
38071000
CY2019Q4 us-gaap Restricted Cash
RestrictedCash
1400000
CY2019Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
42993000
CY2019Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
43100000
CY2020Q1 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
212922000
CY2020Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
213127000
CY2019Q4 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
257078000
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
257299000
CY2020Q1 us-gaap Interest Receivable
InterestReceivable
800000
CY2019Q4 us-gaap Interest Receivable
InterestReceivable
900000
CY2020Q1 atra Write Off Of Accrued Interest Receivable
WriteOffOfAccruedInterestReceivable
0
CY2019 atra Write Off Of Accrued Interest Receivable
WriteOffOfAccruedInterestReceivable
0
CY2020Q1 us-gaap Restricted Cash
RestrictedCash
1400000
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
70203000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
74317000
CY2020Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
194000
CY2019Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
194000
CY2020Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1200000
CY2019Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1200000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
71597000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
75711000
CY2020Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
68009000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
65854000
CY2020Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
13567000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
11678000
CY2020Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
54442000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
54176000
CY2020Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1900000
CY2019Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1600000
CY2020Q1 atra Due To Licensors Current And Noncurrent
DueToLicensorsCurrentAndNoncurrent
0
CY2019Q4 atra Due To Licensors Current And Noncurrent
DueToLicensorsCurrentAndNoncurrent
0
CY2020Q1 atra Accrued Termination Charges
AccruedTerminationCharges
0
CY2019Q4 atra Accrued Termination Charges
AccruedTerminationCharges
0
CY2020Q1 atra Liabilities Related To Indemnification Agreements
LiabilitiesRelatedToIndemnificationAgreements
0
CY2019Q4 atra Liabilities Related To Indemnification Agreements
LiabilitiesRelatedToIndemnificationAgreements
0
CY2020Q1 us-gaap Capital Units Authorized
CapitalUnitsAuthorized
520000000
CY2020Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2020Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000
CY2020Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Terms Of Award
ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward
the exercise price of an option granted to a 10% shareholder cannot be less than 110% of the estimated fair value of the shares on the date of grant. Options granted generally vest over four years and expire in seven to ten years.
CY2020Q1 atra Shareholder Ownership Percent
ShareholderOwnershipPercent
0.10
CY2020Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
16745854
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12644000
CY2019Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12269000

Files In Submission

Name View Source Status
0001564590-20-021960-index-headers.html Edgar Link pending
0001564590-20-021960-index.html Edgar Link pending
0001564590-20-021960.txt Edgar Link pending
0001564590-20-021960-xbrl.zip Edgar Link pending
atra-10q_20200331.htm Edgar Link pending
atra-10q_20200331_htm.xml Edgar Link completed
atra-20200331.xsd Edgar Link pending
atra-20200331_cal.xml Edgar Link unprocessable
atra-20200331_def.xml Edgar Link unprocessable
atra-20200331_lab.xml Edgar Link unprocessable
atra-20200331_pre.xml Edgar Link unprocessable
atra-ex311_9.htm Edgar Link pending
atra-ex312_7.htm Edgar Link pending
atra-ex321_10.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending